Back to Journals » OncoTargets and Therapy » Volume 14

Poor Prognosis of Pulmonary Adenosquamous Carcinoma with NRAS and HRAS Double Mutation

Authors Zhao J, Zhang X, He M, Chen X, Cui X, Qin T, Niu X, Zhao L

Received 4 December 2020

Accepted for publication 22 January 2021

Published 17 February 2021 Volume 2021:14 Pages 1113—1116

DOI https://doi.org/10.2147/OTT.S295813

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Nicola Silvestris


Jidong Zhao,1 Xiangmei Zhang,2 Ming He,1 Xin Chen,1 Xing Cui,1 Tian Qin,3 Xueliang Niu,3 Liyan Zhao4

1Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China; 2Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China; 3Medical Department, Burning Rock Biotech, Guangzhou, People’s Republic of China; 4Department of Internal Medicine, The First Hospital of Xingtai, Xingtai, People’s Republic of China

Correspondence: Xin Chen
Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, No. 12, Jiankang Road, Shijiazhuang, Hebei Province, 050010, People’s Republic of China
Tel +86-13633118699
Email 2029669284@qq.com

Abstract: RAS mutations constitute one of the major tumorigenic mechanisms and are detected in approximately 20% of lung cancers. The most frequent mutated and well-studied RAS isoform is KRAS, which is associated with an overall poor prognosis in non-small-cell lung cancer (NSCLC). However, the clinical significances of NRAS and HRAS in NSCLC are rarely reported. Here, we present a 58-year-old male smoker who was diagnosed with stage IV lung adenosquamous carcinoma. A rare NRAS and HRAS double mutation was detected in the primary tumor and lymph node samples using next-generation sequencing (NGS). The patient showed rapid disease progression and passed away due to respiratory failure after 15 days of osimertinib in combination with cisplatin. To the best of our knowledge, this is the first report associating NRAS and HRAS double mutation in the poor prognosis of NSCLC.

Keywords: NSCLC, NRAS, HRAS

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]